IL312679A - Compounds for the treatment of anemia associated with MDS and other conditions - Google Patents
Compounds for the treatment of anemia associated with MDS and other conditionsInfo
- Publication number
- IL312679A IL312679A IL312679A IL31267924A IL312679A IL 312679 A IL312679 A IL 312679A IL 312679 A IL312679 A IL 312679A IL 31267924 A IL31267924 A IL 31267924A IL 312679 A IL312679 A IL 312679A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- compound
- effective amount
- therapeutically effective
- anemias
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 6
- 208000007502 anemia Diseases 0.000 title claims 4
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280069P | 2021-11-16 | 2021-11-16 | |
| US202263357240P | 2022-06-30 | 2022-06-30 | |
| PCT/US2022/049969 WO2023091414A1 (en) | 2021-11-16 | 2022-11-15 | Compounds for treating mds-associated anemias and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312679A true IL312679A (en) | 2024-07-01 |
Family
ID=84887868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312679A IL312679A (en) | 2021-11-16 | 2022-11-15 | Compounds for the treatment of anemia associated with MDS and other conditions |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250108049A1 (https=) |
| EP (1) | EP4433057A1 (https=) |
| JP (1) | JP2024543345A (https=) |
| KR (1) | KR20240107326A (https=) |
| AU (1) | AU2022390088A1 (https=) |
| CA (1) | CA3236880A1 (https=) |
| CL (1) | CL2024001431A1 (https=) |
| IL (1) | IL312679A (https=) |
| MX (1) | MX2024005852A (https=) |
| TW (1) | TW202329935A (https=) |
| WO (1) | WO2023091414A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202509043A (zh) * | 2023-05-15 | 2025-03-01 | 美商阿吉歐斯製藥公司 | ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式 |
| WO2026076363A1 (en) | 2024-10-04 | 2026-04-09 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| CA2989111C (en) | 2015-06-11 | 2023-10-03 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| TWI796353B (zh) | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| KR102777452B1 (ko) | 2017-11-22 | 2025-03-10 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 |
| WO2020237047A1 (en) | 2019-05-22 | 2020-11-26 | Agios Pharmaceuticals, Inc. | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
-
2022
- 2022-11-15 IL IL312679A patent/IL312679A/en unknown
- 2022-11-15 EP EP22839539.8A patent/EP4433057A1/en active Pending
- 2022-11-15 JP JP2024526836A patent/JP2024543345A/ja active Pending
- 2022-11-15 MX MX2024005852A patent/MX2024005852A/es unknown
- 2022-11-15 CA CA3236880A patent/CA3236880A1/en active Pending
- 2022-11-15 AU AU2022390088A patent/AU2022390088A1/en active Pending
- 2022-11-15 TW TW111143555A patent/TW202329935A/zh unknown
- 2022-11-15 WO PCT/US2022/049969 patent/WO2023091414A1/en not_active Ceased
- 2022-11-15 US US18/711,090 patent/US20250108049A1/en active Pending
- 2022-11-15 KR KR1020247019391A patent/KR20240107326A/ko active Pending
-
2024
- 2024-05-14 CL CL2024001431A patent/CL2024001431A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236880A1 (en) | 2023-05-25 |
| JP2024543345A (ja) | 2024-11-21 |
| EP4433057A1 (en) | 2024-09-25 |
| TW202329935A (zh) | 2023-08-01 |
| CL2024001431A1 (es) | 2024-10-25 |
| US20250108049A1 (en) | 2025-04-03 |
| AU2022390088A1 (en) | 2024-05-09 |
| MX2024005852A (es) | 2024-05-28 |
| WO2023091414A1 (en) | 2023-05-25 |
| KR20240107326A (ko) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stein | Pharmacokinetics and pharmacodynamics of newer fluoroquinolones | |
| EP1019036B1 (en) | Use of d-methionine to reduce the toxicity of ototoxic drugs and noise | |
| US6156755A (en) | Use of pyrimidine derivatives for the prevention of cancer, on their own or in combination with other therapeutic measures | |
| IL312679A (en) | Compounds for the treatment of anemia associated with MDS and other conditions | |
| EP1702621B1 (en) | Metal/Thiol biocides | |
| AU780678B2 (en) | New use of compounds as antibacterial agents | |
| JP2004502752A5 (https=) | ||
| WO2002066480A3 (en) | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders | |
| CA2501322A1 (en) | Quinolinyl-pyrrolopyrazoles | |
| IL300151A (en) | Combinations for cancer treatment | |
| US5334589A (en) | Quinolone carboxylic acid--metal ion--acid complexes | |
| FI3982963T3 (fi) | Koostumus, johon sisältyy pridopidiini ja sen analogi, huntingtonin taudin ja sen oireitten hoitoa varten | |
| US4073922A (en) | Treatment of rheumatoid arthritis and related diseases | |
| EP1177791A3 (en) | Use of glycogen phosphorylase inhibitors to inhibit tumor growth | |
| JP2001513506A5 (https=) | ||
| JP2001513110A (ja) | 腫瘍治療方法 | |
| AU2016295357B2 (en) | Therapeutic combinations of orally administered paclitaxel and a P-gp inhibitor for the treatment of cancer | |
| JP2005527575A5 (https=) | ||
| Kaojarern et al. | Pharmacokinetics of amikacin in hematologic malignancies | |
| JP2024543345A5 (https=) | ||
| AU8424091A (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2-{(3,4-dimethoxy-2-pyridyl) methylsulfinyl} benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| Lacey et al. | Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB) | |
| US5441963A (en) | Potentiation of NMDA antagonists | |
| US5776979A (en) | Method of use of cardiotonic drugs and inhibitors of nitric oxide synthesis to alleviate pathologic hypotension | |
| MacGowan et al. | Sequential antimicrobial therapy: pharmacokinetic and pharmacodynamic considerations in sequential therapy |